证券代码：603707 证券简称：健友股份 编号：2023-001 债券 代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 投资者关系活动记录表 投资者关系 ■特定对象调研 □分析师会议□媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 活动类别 □其他（请文字说明其他活动内容） 公司名称 姓名 公司名称 姓名 公司名称 姓名 兴业证券 黄翰漾 招银理财 熊超逸 富国基金 孙笑悦 鲍尔赛嘉 林炎 兴业证券 杨希成 招银理财 郝雪梅 广发资管 徐默凡 长盛基金 郝征 德汇集团 蔡荣转 HBM 国君资管 吴佳玮 中泰资管 张闻熙 郭牧青 Partners 鲸域资产 万巍 华夏久盈 张伟光 富国基金 周文波 凯丰投资 薛良辰 财通基金 沈犁 峰境基金 魏磊 蜂巢基金 赵花琴 银河基金 施文琪 中海基金 陈玮 汇安基金 高苏 Point72 李大蔚 兴业证券 邹文凯 参与单位名 万纳资产 王立立 东证创金 刘梦杨 远信资本 王楠 ...

2023 年第三季度报告 单位：元 币种：人民币 证券代码：603707 证券简称：健友股份 南京健友生化制药股份有限公司 2023 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|-----------------------------------------|------------------|----------------------------- ...

Financial Performance - Revenue for the first half of 2023 reached RMB 2,303,732,565.40, a year-on-year increase of 16.63%[17] - Net profit attributable to shareholders of the listed company was RMB 624,500,188.97, up 1.70% compared to the same period last year[17] - Net cash flow from operating activities increased by 26.42% to RMB 630,364,246.90[17] - Basic earnings per share increased by 2.63% to 0.39 yuan per share compared to the same period last year[18] - Weighted average return on equity decreased by 1.23 percentage points to 9.63%[18] - Non-recurring gains and losses amounted to 13,173,527.77 yuan, including government subsidies of 15,247,914.63 yuan[21][22] - The company achieved a revenue of 2.30 billion yuan in the first half of 2023, a year-on-year increase of 16.63%, with overseas sales accounting for 73.11% of total revenue at 1.68 billion yuan, and domestic sales at 619 million yuan, accounting for 26.89%[39] - Net profit attributable to the parent company in the first half of 2023 was 624.50 million yuan, a year-on-year increase of 1.70%, driven by growth in the company's formulation sales[39] - The company's U.S. subsidiary, Meitheal, achieved sales revenue exceeding 800 million yuan in the first half of 2023, a year-on-year increase of 49.70%[40] - The company's CDMO business revenue grew by over 40% in the first half of 2023, driven by strategic collaborations with global clients[40] - The company achieved a revenue of 2.30 billion yuan in the first half of 2023, a year-on-year increase of 16.63%, with a net profit of 624.50 million yuan, up 1.70% year-on-year[62] - R&D investment in the reporting period was 163.52 million yuan, a year-on-year increase of 24.17%, with a strong R&D team of over 500 people[63] - Revenue increased by 16.63% year-on-year to RMB 2.30 billion in the first half of 2023[69] - R&D expenses grew by 42.46% year-on-year to RMB 150.81 million, reflecting increased investment in innovation[69] - Net profit attributable to the parent company's shareholders was 624,500,188.97 RMB in the first half of 2023, a 1.7% increase from 614,035,642.75 RMB in the same period of 2022[181] - Basic earnings per share (EPS) for the first half of 2023 was 0.39 RMB, compared to 0.38 RMB in the same period of 2022[182] - Total comprehensive income for the first half of 2023 was 629,782,766.18 RMB, a 3.0% increase from 611,113,416.38 RMB in the same period of 2022[182] - Sales expenses rose by 21.4% to 261,555,451.30 RMB in the first half of 2023, compared to 215,454,959.30 RMB in the same period of 2022[178] - Financial expenses showed a net income of 85,700,841.49 RMB in the first half of 2023, compared to 69,193,979.94 RMB in the same period of 2022[178] - The company's total profit for the first half of 2023 was 738,348,951.76 RMB, a 3.2% increase from 715,422,314.44 RMB in the same period of 2022[180] - Income tax expenses increased by 11.7% to 113,834,452.06 RMB in the first half of 2023, compared to 101,951,732.21 RMB in the same period of 2022[180] - Comprehensive income for the first half of 2023 was RMB 510,085,407.48, compared to RMB 606,570,546.08 in the same period last year[185] - Cash flow from operating activities in the first half of 2023 was RMB 630,364,246.90, an increase from RMB 498,607,712.27 in the same period last year[187] - Cash received from sales of goods and services in the first half of 2023 was RMB 2,233,827,146.83, slightly up from RMB 2,178,973,884.58 in the same period last year[186] - Cash paid for goods and services in the first half of 2023 was RMB 1,189,538,431.81, compared to RMB 1,165,380,748.61 in the same period last year[186] - Cash flow from investing activities in the first half of 2023 was negative RMB 37,997,140.78, an improvement from negative RMB 511,030,540.94 in the same period last year[187] - Cash flow from financing activities in the first half of 2023 was negative RMB 298,667,663.85, compared to positive RMB 460,818,279.85 in the same period last year[188] - Net increase in cash and cash equivalents in the first half of 2023 was RMB 307,213,181.99, down from RMB 460,170,306.18 in the same period last year[188] - Cash received from tax refunds in the first half of 2023 was RMB 133,893,037.17, slightly down from RMB 144,194,652.57 in the same period last year[186] - Cash paid to employees in the first half of 2023 was RMB 194,191,605.46, up from RMB 148,338,042.47 in the same period last year[186] - Cash paid for taxes in the first half of 2023 was RMB 178,577,981.96, down from RMB 225,256,986.06 in the same period last year[186] - Net cash flow from investment activities was -36.65 million yuan, compared to 27.25 million yuan in the same period last year[190] - Net cash flow from financing activities was -125.01 million yuan, compared to -67.19 million yuan in the same period last year[190] - The net increase in cash and cash equivalents was 99.64 million yuan, compared to 259.20 million yuan in the same period last year[190] - The total comprehensive income for the period was 629.78 million yuan[192] - The company allocated 185.91 million yuan for profit distribution to shareholders[192] - The total owner's equity at the end of the period was 6.61 billion yuan, an increase from 6.17 billion yuan at the beginning of the period[194] - The company's capital reserve decreased by 3.11 million yuan during the period[192] - The company's undistributed profit increased by 438.59 million yuan during the period[192] - The company's special reserve increased by 71,567.71 yuan during the period[194] - The company's total liabilities and owner's equity at the end of the period was 6.61 billion yuan[194] - The company's total comprehensive income for the first half of 2023 was RMB 607,000,464.30[196] - The company allocated RMB 186,585,548.70 for profit distribution to shareholders[197] - The company's total owner's equity at the end of the period was RMB 5,858,103,612.41[198] - The company's capital reserve increased by RMB 11,928,122.64 during the period[196] - The company's undistributed profit decreased by RMB 7,035,178.45[196] - The company's special reserve increased by RMB 4,116,209.04[198] - The company's total owner's equity at the beginning of the period was RMB 5,402,757,039.30[196] - The company's capital stock increased by RMB 303,438.00[196] - The company's other comprehensive income decreased by RMB 196.10[196] - The company's total owner's equity increased by RMB 455,346,573.11 during the period[196] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 11,095,253,855.79, a 10.84% increase from the end of the previous year[17] - Equity attributable to shareholders of the listed company grew by 7.22% to RMB 6,616,095,822.22[17] - Cash and cash equivalents increased by 26.13% to 1,751,303,798.14 yuan, accounting for 15.78% of total assets[72] - Trading financial assets surged by 36,076.92% to 470,300,000.00 yuan due to increased financial product purchases[72] - Accounts receivable increased by 386.68% to 107,117,814.94 yuan, driven by higher receivables from bills[72] - Prepayments rose by 260.53% to 90,370,653.36 yuan due to increased advance payments for goods[72] - Other receivables grew by 21.42% to 293,760,741.65 yuan, mainly due to increased cooperation funds from Europe and the US[72] - Fixed assets increased by 29.03% to 1,200,956,552.04 yuan, primarily due to the transfer of construction in progress to fixed assets[72][73] - Construction in progress decreased by 92.77% to 18,119,509.44 yuan, as projects were transferred to fixed assets[73] - The company's monetary funds increased to 1,751,303,798.14 yuan as of June 30, 2023, compared to 1,388,512,343.62 yuan at the end of 2022[167] - The company's total assets reached 11,095,253,855.79 yuan as of June 30, 2023, up from 10,010,102,945.14 yuan at the end of 2022[169] - The company's short-term borrowings increased to 2,251,789,666.36 yuan as of June 30, 2023, compared to 1,956,863,361.92 yuan at the end of 2022[169] - The company's accounts receivable increased to 1,009,863,891.94 yuan as of June 30, 2023, up from 952,098,814.39 yuan at the end of 2022[167] - The company's inventory decreased slightly to 5,555,576,976.64 yuan as of June 30, 2023, compared to 5,615,601,457.76 yuan at the end of 2022[168] - The company's fixed assets increased to 1,200,956,552.04 yuan as of June 30, 2023, up from 930,727,070.81 yuan at the end of 2022[168] - The company's total current liabilities increased to 3,340,928,333.11 yuan as of June 30, 2023, compared to 2,704,653,975.08 yuan at the end of 2022[169] - The company's development expenditure increased to 107,377,228.39 yuan as of June 30, 2023, up from 93,236,418.69 yuan at the end of 2022[168] - The company's total non-current assets reached 1,773,423,903.42 yuan as of June 30, 2023, compared to 1,716,038,381.10 yuan at the end of 2022[169] - Total liabilities increased to 4,482,609,220.14 RMB, up from 3,842,932,928.85 RMB in the previous period[170] - Total owner's equity (or shareholder's equity) reached 6,612,644,635.65 RMB, compared to 6,167,170,016.29 RMB previously[171] - Monetary funds increased to 184,669,804.14 RMB from 104,262,654.92 RMB[172] - Accounts receivable rose to 1,455,326,689.74 RMB from 1,200,080,987.96 RMB[172] - Inventory decreased slightly to 4,868,512,114.20 RMB from 4,987,456,425.34 RMB[172] - Total assets amounted to 8,557,447,770.81 RMB, up from 8,427,634,697.16 RMB[173] - Short-term borrowings decreased significantly to 280,957,623.00 RMB from 723,286,608.02 RMB[173] - Long-term borrowings remained stable at 500,000,000.00 RMB[174] - Total owner's equity (or shareholder's equity) increased to 6,152,857,564.88 RMB from 5,827,080,304.22 RMB[175] Product Portfolio and Market Expansion - The company has 86 overseas drug registration certificates and 26 Chinese drug registration certificates[26] - The company's product pipeline includes low molecular weight heparin preparations, anti-tumor preparations, and other high-value-added sterile injections[26] - The company's heparin sodium injection is approved in the US for anticoagulation and antithrombosis[27] - Enoxaparin sodium injection is approved in multiple countries including the US, UK, Germany, and Canada for the prevention of venous thromboembolism[27] - The company's dalteparin sodium injection is approved in China for the treatment of acute deep vein thrombosis and prevention of thrombosis related to surgery[27] - The company's nadroparin calcium injection is approved in China for the prevention of thrombosis and treatment of deep vein thrombosis[27] - The company's atracurium besylate injection is approved in the US for skeletal muscle relaxation during general anesthesia[27] - The company's product portfolio includes 50 injectable drugs, with 38 approved in the US market and 12 in the Chinese market[29][30][31][32] - Key products include Bendamustine Hydrochloride for Injection (used in the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma) and Mitomycin for Injection (used in the treatment of gastric cancer, lung cancer, breast cancer, etc.)[29][31] - The company is expanding its presence in the European and global markets, particularly with the registration of enoxaparin formulations in more countries[32] - The company maintains long-term stable supply relationships with major global heparin preparation manufacturers, including Pfizer, Gland, and Sanofi[32] - Heparin API business serves as a cash flow provider and foundation for the company's sterile injectable domestic and international expansion[32] - The company obtained multiple drug registration approvals, including Niraparib Injection, Rocuronium Bromide Injection, Bendamustine Hydrochloride for Injection, and Plerixafor Injection, further enriching its product pipeline[39] - The company's CDMO business focuses on providing differentiated biopharmaceutical CDMO services in regulated markets, leveraging global regulatory experience to capture higher-value service revenues[33] - The company established a Biopharmaceutical Division with platforms for protein design, drug delivery systems, molecular biology, and cell biology to enhance innovation capabilities[34] - The company's sterile injection production lines are certified by the U.S. FDA and comply with GMP and cGMP standards, ensuring product quality and safety[36] - The company's domestic formulation sales benefited from the centralized procurement policy, with products like Enoxaparin Sodium Injection and Nadroparin Calcium Injection winning bids in the 8th national drug procurement round[40] - The company's global CDMO business targets sterile injection R&D and production, serving global pharmaceutical companies and domestic innovators with a focus on expanding market demand and reducing costs[38] - The company's products are primarily focused on the anticoagulant and oncology markets, which have significant growth potential[45] - The company provides CDMO services to global and domestic pharmaceutical companies, leveraging advanced process R&D capabilities and production facilities[48] - The company has over 500 R&D personnel, including more than 80 with master's or doctoral degrees, and collaborates with R&D teams in the US and Israel[54] - The company operates four R&D centers in Nanjing, Chengdu, the US, and Israel, focusing on nucleic acid-based therapies, monoclonal antibody development, biopharmaceutical innovation, and clinical research respectively[54] - The company has established a peptide drug R&D platform using solid-phase synthesis technology, covering anticoagulation, reproductive, endocrine, and rare disease biologics[55] - The company has developed advanced complex formulation platforms, including sustained-release injections, liposomes, and auto-injector technologies[55] - The company has a strong track record of obtaining ANDA approvals, ranking first among domestic peers in the number of ANDA approvals[56] - The company has successfully launched generic drugs before the expiration of original patents, accelerating market penetration and product pipeline development[56] - The company's R&D strategy focuses on expanding from heparin-based products to oncology, immunomodulation, metabolic, digestive, and central nervous system diseases, while exploring nucleic acid-based drugs[54] - The company has 6 FDA-approved production lines with high automation and stable processes, significantly improving production efficiency and quality[57] - The company completed the acquisition of Meitheal, enhancing its overseas marketing channels and understanding of the US market[59] - Meitheal has established long-term stable relationships with GPOs, IDN/PNs, and the top three US wholesalers, supporting rapid growth in US sales[60] - The company has a complete sales channel and operational experience in the US market, with localized marketing strategies and deep integration with Meitheal[60] - The company is expanding its CDMO capabilities, attracting global and domestic pharmaceutical companies with its marketing and product development capabilities[61] - The company is optimizing its product structure and expanding production capacity through FDA-approved projects, enhancing its market position and competitiveness[58] - The company has 12 R&D projects in progress, with 7 projects in the stability testing phase and 5 projects under regulatory approval[64] - 7 drugs were approved by the US FDA during the reporting period, including Plerixafor Injection and Bupivacaine Hydrochloride Injection[64] - The company's US subsidiary achieved sales revenue exceeding RMB 800 million in the first half of 2023, a year-on-year increase of 49.70%[

南京健友生化制药股份有限公司 2022 年年度报告 1 / 305 公司代码：603707 公司简称：健友股份 南京健友生化制药股份有限公司 2022 年年度报告 以国际能力，切入国际药品市场 股票简称:健友股份 股票代码: 603707 南京健友生化制药股份有限公司 2022 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 中天运会计师事务所（特殊普通合伙） 为本公司出具了标准无保留意见的审计报告。 四、 公司负责人唐咏群、主管会计工作负责人钱晓捷及会计机构负责人（会计主管人员）顾小梅 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 以实施权益分派股权登记日的总股本为基数，向全体股东每10股派发现金股利1.15元（含税 ），该预案尚需提交2022年年度股东大会审议批准。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构 ...

2023 年第一季度报告 单位：元 币种：人民币 证券代码：603707 证券简称：健友股份 南京健友生化制药股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|------------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增 减变动幅度 (%) | | 营业收入 | 1,307,482,631.58 ...